<\/p><\/td> | <\/p><\/td> | <\/p><\/td> | £0.44<\/p><\/td> | £0.50<\/p><\/td><\/tr><\/tbody><\/table> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-11-02", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "183920"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-02T13:36:14.267Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Radiotherapy: Medical Treatments Abroad"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how much his Department spent on travel and accommodation for adults taking part in the NHS Proton Beam Therapy Service Overseas programme in (a) 2010, (b) 2015, (c) 2016 and (d) 2017.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3985", "label" : {"_value" : "Biography information for Robert Halfon"}
}
, "tablingMemberConstituency" : {"_value" : "Harlow"}
, "tablingMemberPrinted" : [{"_value" : "Robert Halfon"}
], "uin" : "183919"}
, {"_about" : "http://data.parliament.uk/resources/994563", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/994563/answer", "answerText" : {"_value" : "NHS England\u2019s financial data for the National Health Service Proton Beam Therapy (PBT) Service Overseas programme does not differentiate between adults and children. Data for 2010 data is unavailable as this is before the creation of NHS England.<\/p> <\/p> The costs per year from 2013/14 to 2017/18 are in the following table.<\/p> <\/p> Cost of PBT Overseas patients 2013/14 to 2017/18 (£ million)<\/p> 2013/14<\/p><\/td> | 2014/15<\/p><\/td> | 2015/16<\/p><\/td> | 2016/17<\/p><\/td> | 2017/18<\/p><\/td><\/tr> | £9.13<\/p><\/td> | £12.63<\/p><\/td> | £20.81<\/p><\/td> | £24.51<\/p><\/td> | £22.75<\/p><\/td><\/tr><\/tbody><\/table> <\/p> This includes accommodation.<\/p> <\/p> Travel cost figures are available in the following table. It should be noted that figures are only available for 2016/17 and 2017/18.<\/p> <\/p> Cost of PBT Overseas patients travel 2013/14 to 2017/18 (£ thousand)<\/p> 2013/14<\/p><\/td> | 2014/15<\/p><\/td> | 2015/16<\/p><\/td> | 2016/17<\/p><\/td> | 2017/18<\/p><\/td><\/tr> | <\/p><\/td> | <\/p><\/td> | <\/p><\/td> | £0.44<\/p><\/td> | £0.50<\/p><\/td><\/tr><\/tbody><\/table> <\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-11-02", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "183919"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-02T13:36:14.33Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Radiotherapy: Medical Treatments Abroad"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how much his Department spent on travel and accommodation for children taking part in the NHS Proton Beam Therapy Service Overseas programme in (a) 2010, (b) 2015, (c) 2016 and (d) 2017.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3985", "label" : {"_value" : "Biography information for Robert Halfon"}
}
, "tablingMemberConstituency" : {"_value" : "Harlow"}
, "tablingMemberPrinted" : [{"_value" : "Robert Halfon"}
], "uin" : "183920"}
, {"_about" : "http://data.parliament.uk/resources/994574", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/994574/answer", "answerText" : {"_value" : "Clinicians are uniquely placed to explain to individual patients what treatments might or might not benefit them, with reference to their circumstances. NHS England is working with providers, patient groups and manufacturers to ensure appropriate information is made available to help clinicians and patients make informed treatment decisions as Chimeric Antigen Receptor T Cell (CAR-T) therapy starts to be made available through the National Health Service.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-11-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-02T13:31:33.48Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Blood Cancer: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what information is provided by NHS England to patients with blood cancer on CAR-T cell therapies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1383", "label" : {"_value" : "Biography information for Mark Tami"}
}
, "tablingMemberConstituency" : {"_value" : "Alyn and Deeside"}
, "tablingMemberPrinted" : [{"_value" : "Mark Tami"}
], "uin" : "183879"}
, {"_about" : "http://data.parliament.uk/resources/994628", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/994628/answer", "answerText" : {"_value" : " NHS England is working with the manufacturers and National Health Service providers to prepare the NHS to begin delivering Chimeric Antigen Receptor T Cell (CAR-T) therapy - the first in a wave of treatments in a new era of personalised medicine and part of the NHS\u2019s long-term plan to upgrade cancer service. The first treatment that will be available to patient is tisagenlecleucel (Kymriah) as an option for treating children and young people up to 25 years old with B cell acute lymphoblastic leukaemia that is refractory, in relapsed post-transplant or in second or later relapse.<\/p> <\/p> NHS England anticipates that the National Institute for Health and Care Excellence will recommend this treatment for entry into the Cancer Drugs Fund in mid-November. If so, funding will be made immediately available, following a successful commercial deal with the manufacturer Novartis. We anticipate the first patients will begin their treatment in late November 2018. The phased implementation required by the manufacturer and the NHS means that full capacity to treat eligible patients will take some months to achieve and a National CAR-T Clinical Panel will convene in mid-November to assure equity of access and prioritise eligible patients.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-11-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-02T13:32:27.747Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Blood Cancer: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the NHS England news releases of 5 September and 5 October, when he plans to make CAR-T cell therapy available to (a) people aged under 25 with acute lymphoblastic leukaemia and (b) adult patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after two or more previous therapies have failed.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3960", "label" : {"_value" : "Biography information for Henry Smith"}
}
, "tablingMemberConstituency" : {"_value" : "Crawley"}
, "tablingMemberPrinted" : [{"_value" : "Henry Smith"}
], "uin" : "183918"}
, {"_about" : "http://data.parliament.uk/resources/994630", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/994630/answer", "answerText" : {"_value" : " The Tobacco Control Plan 2017-2022 published last year commits the Government to reduce the inequality gap in smoking prevalence between those in routine and manual occupations and the general population. Smoking cessation treatment is one part of the comprehensive approach to tobacco control required to achieve this ambition.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-11-02", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-11-02T13:39:16.037Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Smoking: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of smoking cessation treatments on health inequalities in the UK; and if he will make an estimate of the relative uptake of smoking cessation treatments by socio-economic group.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "tablingMemberConstituency" : {"_value" : "North Norfolk"}
, "tablingMemberPrinted" : [{"_value" : "Norman Lamb"}
], "uin" : "183884"}
, {"_about" : "http://data.parliament.uk/resources/994661", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/994661/answer", "answerText" : {"_value" : " The Department has made no such assessment. The section of NHS England\u2019s guidance which covers head lice says that chemical treatment for them is only used in exceptional cases; the usual treatment is wet combing. NHS England undertook an Equalities and Health Inequalities analysis \u2018Conditions for which over the counter items should not be routinely prescribed in primary care: Equality and health inequalities full analysis form\u2019 alongside the guidance, which assessed the impact of the guidance on those from low income households and those living in poverty. The analysis can be accessed using the following link:<\/p> <\/p> https://www.england.nhs.uk/wp-content/uploads/2018/03/otc-ehi-analysis-form.pdf<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-31", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-31T12:08:25.84Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-25", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Head Lice"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the oral contribution of 25 October 2018 of the hon. Member for Kingston upon Hull West and Hessle, Official Report, column 456, what assessment he has made of the effect that recent changes to NHS guidance to Clinical Commissioning Groups on conditions for which over the counter items should not routinely be prescribed in primary care will have on the spread of headlice in deprived areas.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4645", "label" : {"_value" : "Biography information for Emma Hardy"}
}
, "tablingMemberConstituency" : {"_value" : "Kingston upon Hull West and Hessle"}
, "tablingMemberPrinted" : [{"_value" : "Emma Hardy"}
], "uin" : "183990"}
, {"_about" : "http://data.parliament.uk/resources/994008", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/994008/answer", "answerText" : {"_value" : "The Government is concerned by the increase in deaths related to the misuse of prescription opioids. The Department has commissioned a review of prescription drug dependence from Public Health England to help understand the scope of the problem. The review will provide a strong evidence base for future policy development in this area.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-10-29T17:49:06.083Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prescription Drugs: Misuse"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to his Answer of 23 April 2018 to Question 136107 on Prescription Drugs: Misuse, what steps his Department is taking to tackle the increase in deaths caused by the consumption of an excess of prescription drugs being the primary cause.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"}
}
, "tablingMemberConstituency" : {"_value" : "East Londonderry"}
, "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"}
], "uin" : "183285"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-AnswerDate=2018-10-29&min-questionFirstAnswered.=2018-10-24T12%3A35%3A34.6Z&answer.answeringMember.label=Biography+information+for+Steve+Brine", "page" : 0, "startIndex" : 1, "totalResults" : 126, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|
|
|